The indictment charges that Ramos andWilliams bribed Gary and Kelly Alexander with cash, a Rolex watch and otheritems of value in return for Gary Alexander’s using his influence at SPAWAR toensure the hiring of TLC as a subcontractor on several projects, including amilitary drug enforcement project based in Key West, Fla. A federal grand jury sitting in San Diego handed up theindictment on June 30, 2009, which was sealed until their arrests earliertoday.According to the indictment, federal employees Gary Alexander and his wife,Kelly Alexander, worked at SPAWAR and for almost eight years accepted cashbribes and other items of value from individuals seeking employment asgovernment subcontractors. Indictment Charges Civilian Navy Employees and Contractors With Fraud andBriberySAN DIEGO, July 7 /PRNewswire-USNewswire/ — U.S Attorney Karen P. Hewittannounced today the unsealing of a 25-count indictment charging sixindividuals with corruption and fraud charges related to defense contractingat Space and Naval Warfare Systems Command (SPAWAR), a government organizationbased in San Diego that is responsible for the development of technology tocollect, process, display and manage information essential to successfulmilitary operations. An important part of the company’s extensive training and education programs,the first 100 sessions of Academy have given nearly 30,000 teammates anopportunity to meet and learn from other DaVita teammates and have a greaterunderstanding of DaVita as a company – and most importantly – as a village. (NYSE: DVA), a leadingprovider of kidney care services for those diagnosed with chronic kidneydisease (CKD), today opened its 100th DaVita Academy – the company’saward-winning, leadership development and cultural orientation program for newteammates (employees).On hand to participate and honor DaVita’s commitmentto teammate empowerment and engagement are former United States Senator PaulSarbanes and Congressman Elijah Cummings.(Logo: http://)DaVita Academy is a two-day experience for new and recently hired DaVita(R)teammates and involves skill building, team building, and having lots of fun.

Senator Paul Sarbanes and Congressman Elijah Cummings Join theProgram for DaVita’s Leadership Development and Cultural Orientation ProgramBALTIMORE, July 7 /PRNewswire-FirstCall/ — DaVita Inc. DaVita’s Award-Winning Training Program for New Teammates Reaches MilestoneWith 100th DaVita Academy in Baltimore, MarylandFormer U.S. 2007;109:2334-2342(4)GVD/Barber ISPOR 2008 Poster; Schulman 2007; Delea et al. 2006 Amgen, Thousand OaksLisa Rooney, 805-447-6437 (media)Arvind Sood, 805-447-1060 (investors)(Logo: http://)SOURCEAmgenmedia, Lisa Rooney, +1-805-447-6437, or investors, Arvind Sood,+1-805-447-1060, both of Amgen, Thousand Oaks.

Textbook of Bone Metastases.Hoboken, NJ:Edition: John Wiley and Sons; 2005:105 (2)Mundy GR. Metastasis to bone: causes, consequences and therapeuticopportunities Nat Rev Cancer 2002 Aug;2(8):584-93.(3)Schulman K and Kohles J Cancer. Healthcare professionals should refer to and rely upon the FDA-approvedlabeling for the products, and not the information discussed in this newsrelease.ZOMETA is a registered trademark of Novartis Oncology.*Editors Note: The FDA has provisionally approved the trade name Prolia(TM)for the proposed indications of treatment and prevention of osteoporosis inpostmenopausal women, and treatment and prevention of bone loss in patientsundergoing hormone ablation for non-metastatic prostate or breast cancer, forwhich denosumab is administered twice yearly subcutaneously at a 60 mg dose.The Prolia(TM) trade name is only for these indications and may not apply forother indications of denosumab (1)Capanna R, Coia LR, Coleman R et al eds. Food and Drug Administration (FDA) forthe products.The products are not approved for the investigational use(s)discussed in this news release, and no conclusions can or should be drawnregarding the safety or effectiveness of the products for these uses.Onlythe FDA can determine whether the products are safe and effective for theseuses. Food and Drug Administration (FDA), and noconclusions can or should be drawn regarding the safety or effectiveness ofthe product candidates.Only the FDA can determine whether the productcandidates are safe and effective for the use(s) being investigated.Further,the scientific information discussed in this news release relating to newindications for our products is preliminary and investigative and is not partof the labeling approved by the U.S. legislation affectingpharmaceutical pricing and reimbursement.Government and others’ regulationsand reimbursement policies may affect the development, usage and pricing ofour products.In addition, we compete with other companies with respect tosome of our marketed products as well as for the discovery and development ofnew products.We believe that some of our newer products, product candidatesor new indications for existing products, may face competition when and asthey are approved and marketed. We develop product candidates internally and through licensingcollaborations, partnerships and joint ventures.